221 filings
Page 4 of 12
S-3/A
zkl9sp6rri3qx p1o
5 Aug 21
Shelf registration (amended)
4:48pm
8-K
379axis0
5 Aug 21
Athenex Provides Second Quarter 2021 Corporate and Financial Update
7:50am
CORRESP
9s75 bk2v
5 Aug 21
Correspondence with SEC
12:00am
UPLOAD
sgrri
30 Jul 21
Letter from SEC
12:00am
S-8
2p9goo8d dku2tu
27 Jul 21
Registration of securities for employees
4:44pm
S-3
0alo0mbgxds 59
27 Jul 21
Shelf registration
12:00am
8-K/A
rfltu59a1
20 Jul 21
Financial Statements and Exhibits
4:29pm
8-K
dla mvj6wstop0xmw2
23 Jun 21
Departure of Directors or Certain Officers
4:05pm
8-K
71a1rdhi
6 May 21
Athenex Provides First Quarter 2021 Corporate and Financial Update
7:16am
8-K
2qay0lvl o1wv0n2hl
5 May 21
Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform
12:00am
8-K
yrcuy6m85 41wa
1 Mar 21
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
7:30am
8-K
b22gdgv
18 Feb 21
Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin
9:30am
8-K
53batr
5 Nov 20
FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer
7:30am
8-K
8bu4w
10 Sep 20
Athenex, Inc. Announces Proposed Public Offering of Common Stock
5:24pm
424B5
88fpe3
10 Sep 20
Prospectus supplement for primary offering
4:06pm